Publications by authors named "E Duke Dickerson"
Angiosarcomas are a group of vascular cancers that form malignant blood vessels. These malignancies are seemingly inflamed primarily due to their pathognomonic nature, which consists of irregular endothelium and tortuous blood channels. PIK3CA mutations are oncogenic and disrupt the PI3K pathway.
View Article and Find Full Text PDFArticle Synopsis
- SARS-CoV-2 vaccinations have decreased hospitalization and death rates in nursing home residents, but effectiveness is challenged by new variants and reduced immunity.
- A study evaluated the immune response to the XBB.1.5 monovalent vaccine in nursing home residents and healthcare workers, focusing on those with prior infections.
- Results showed a significant increase in neutralizing antibody levels, especially in nursing home residents who had a previous infection, indicating the vaccine's ability to enhance immunity against Omicron variants.
Article Synopsis
- Hemangiosarcoma in dogs and angiosarcoma in humans are aggressive sarcomas originating from blood vessel-forming cells, characterized by disorganized vascular spaces and high metastasis rates.
- The study used dog-in-mouse xenografts to mimic the tumors' properties, observing the complex interaction between donor and host cells, which led to the development of myeloid hyperplasia and lymphoproliferative tumors.
- Findings suggest that these sarcomas create a supportive microenvironment for hematopoietic (blood cell) growth, indicating a potential role in tumor progression by regulating surrounding stromal and immune responses.
Background: SARS-CoV-2 vaccination has reduced hospitalization and mortality for nursing home residents (NHRs). However, emerging variants coupled with waning immunity, immunosenescence, and variability of vaccine efficacy undermine vaccine effectiveness. We therefore need to update our understanding of the immunogenicity of the most recent XBB.
View Article and Find Full Text PDFBackground: Mutations in the receptor tyrosine kinase gene fibroblast growth factor receptor 2 (FGFR2) occur at a high frequency in endometrial cancer (EC) and have been linked to advanced and recurrent disease. However, little is known about how these mutations drive carcinogenesis.
Methods: Differential transcriptomic analysis and two-step quantitative real-time PCR (qRT-PCR) assays were applied to identify genes differentially expressed in two cohorts of EC patients carrying mutations in the FGFR2 gene as well as in EC cells harbouring mutations in the FGFR2.